@article{S_D_2020, title={COMPARATIVE STUDY ON RAMIPRIL AND TELMISARTAN-ASSOCIATED HYPONATREMIA}, volume={13}, url={https://journals.innovareacademics.in/index.php/ajpcr/article/view/39848}, DOI={10.22159/ajpcr.2020.v13i12.39848}, abstractNote={<p><strong>Objectives: </strong>This study was planned to study the association of ramipril and telmisartan with hyponatremia and to compare the hyponatremia effect of ramipril and telmisartan.</p> <p><strong>Methods: </strong>The study was conducted in a tertiary care hospital. Serum sodium levels were assayed in patients taking ramipril and telmisartan. Fifty-one patients were recruited. The patient’s age, gender, drug dosage, and frequency of drug administration were collected using a pro forma. Statistical analysis of data was performed using SPSS version 23.0.</p> <p><strong>Results: </strong>About 35.3% (28 out of 51) of the study population administered with ramipril and telmisartan developed hyponatremia. Predisposition to develop hyponatremia was high in males compared to females. Incidence of hyponatremia was 43.8% (7 out of 16) in the age group of 50–60 years. Although, incidence of hyponatremia was 56.5% (13 out of 23) in ramipril group compared to 17.9% (5 out of 28) in telmisartan group, it was not statistically significant.</p> <p><strong>Conclusion: </strong>The current study laid emphasis on the requisite for monitoring of serum sodium level in patients on ramipril and telmisartan administration to avoid morbidity and mortality due to unexpected adverse reactions.</p>}, number={12}, journal={Asian Journal of Pharmaceutical and Clinical Research}, author={S, BHUVANESHWARI and D, VIJAYA}, year={2020}, month={Dec.}, pages={162–164} }